Notes d’épisode
Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

